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Abstract: Overdiagnosis and overtreatment of clinically insignificant tumors remains a major problem
in prostate cancer (PC) due to suboptimal diagnostic and prognostic tools. Thus, novel biomarkers
are urgently needed. In this study, we investigated the biomarker potential of Trefoil factor 3 (TFF3)
promoter methylation and RNA expression levels for PC. Initially, by quantitative methylation specific
PCR (qMSP) analysis of a large radical prostatectomy (RP) cohort (n = 292), we found that the TFF3
promoter was significantly hypomethylated in PC compared to non-malignant (NM) prostate tissue
samples (p < 0.001) with an AUC (area under the curve) of 0.908 by receiver operating characteristics
(ROC) curve analysis. Moreover, significant TFF3 promoter hypomethylation (p ≤ 0.010) as well
as overexpression (p < 0.001) was found in PC samples from another large independent patient
sample set (498 PC vs. 67 NM) analyzed by Illumina 450K DNA methylation arrays and/or
RNA sequencing. TFF3 promoter methylation and transcriptional expression levels were inversely
correlated, suggesting that epigenetic mechanisms contribute to the regulation of gene activity.
Furthermore, low TFF3 expression was significantly associated with high ERG, ETS transcription
factor (ERG) expression (p < 0.001), as well as with high Gleason score (p < 0.001), advanced
pathological T-stage (p < 0.001), and prostate-specific antigen (PSA) recurrence after RP (p = 0.013;
univariate Cox regression analysis). There were no significant associations between TFF3 promoter
methylation levels, ERG status, or PSA recurrence in these RP cohorts. In conclusion, our results
demonstrated diagnostic biomarker potential of TFF3 promoter hypomethylation for PC as well
as prognostic biomarker potential of TFF3 RNA expression. To the best of our knowledge, this is
the most comprehensive study of TFF3 promoter methylation and transcriptional expression in PC
to date.
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1. Introduction
Prostate cancer (PC) is the most common non-skin cancer and the third most lethal malignancy
amongst European men [1]. Some PCs remain latent and cause no significant symptoms or risk
of morbidity within the lifetime of the patients, while other PCs progress to aggressive metastatic
disease. Localized PC is curable by radical prostatectomy (RP) or radiation therapy, but only palliative
treatments are available for metastatic PC. Therefore, early detection of PC is crucial. However,
currently available diagnostic and prognostic tools for PC are suboptimal resulting in overdiagnosis
and overtreatment of many clinically insignificant PCs [2]. Thus, there is an urgent need for novel
diagnostic and prognostic biomarkers for PC.
Aberrant DNA hypermethylation of CpG island-containing gene promoters is a hallmark for
PC and other malignancies, whereas non-CpG island promoters may become either hyper- or
hypomethylated in cancer cells [3]. Some of the genes affected by perturbed promoter methylation
levels are potential tumor suppressors or drivers of PC, as their transcriptional expression is repressed
or activated upon promoter hyper- or hypomethylation, respectively [4]. In recent years, several
candidate promoter hypermethylation markers for PC diagnosis have been identified [5–10], some of
which have also shown promising prognostic potential for prediction of prostate-specific antigen (PSA)
recurrence after RP [5,6,8,11–14]. Likewise, aberrant promoter hypomethylation has been proposed as
a cancer biomarker in, e.g., myelofibrosis [15] and glioma [16], but it has not been extensively studied
for PC.
The Trefoil factor 3 (TFF3) gene has a non-CpG island promoter and encodes the TFF3 protein,
also known as intestinal trefoil factor, which is part of the mammalian family of trefoil factors
(TFF1–3) [17]. TFF3 is a small secreted peptide that is present in almost all mucin-secreting tissues, but
is most abundant in goblet cells of the gastrointestinal tract, where it protects the epithelial barrier by
stimulation of mucosal restitution and inhibition of apoptosis [18–21]. In relation to cancer, TFF3 has
been proposed to function both as an oncogene and as a tumor suppressor. Thus, high TFF3 expression
has been associated with favorable prognosis in ovarian cancer [22] and with low grade in early stage
breast cancer [23], and TFF3 seems to act as a tumor suppressor in thyroid cancer [24]. In contrast,
TFF3 protein overexpression has been linked with aggressive disease in colon, gastric, and mammary
cancer [25–28]. Likewise, overexpression studies in cell line models have suggested that TFF3 serves
as an oncogene in advanced metastatic castration-resistant PC [29]. However, three independent
tissue microarray (TMA) studies of early stage hormone-naive PC (n = 268, n = 235, and n = 96
RP samples, respectively) showed no significant association between TFF3 protein levels and PSA
recurrence after RP [30–32]. Furthermore, TFF3 protein expression has been reported to be significantly
up-regulated only in the subset of PCs that are negative for the TMPRRS2-ERG (transmembrane
protease, serine 2-ERG, ETS-transcription factor) gene fusion, which occurs in approximately 50% of
primary PCs [33,34], potentially further complicating the possible association of TFF3 protein levels
with prognosis as ERG fusion status is not clearly associated with PC outcome after RP [35].
Although we have previously reported that the TFF3 promoter is hypomethylated in PC tissue
samples, this was based only on a small patient sample set (10 PC vs. 12 benign prostatic hyperplasia
(BPH) tissue samples) [36]. In the same study, we showed that TFF3 promoter methylation and RNA
expression levels were inversely correlated in a small set of prostate (cancer) cell lines, suggesting
epigenetic regulation of gene activity [36]. However, larger patient sample sets are needed to investigate
the diagnostic and prognostic biomarker potential of TFF3 promoter methylation and RNA expression
in PC.
Accordingly, in the present study, we have evaluated TFF3 promoter hypomethylation and RNA
expression in multiple large PC patient cohorts. First, using quantitative methylation specific PCR
(qMSP) analysis, we found highly frequent and cancer-specific TFF3 promoter hypomethylation in
a set of 292 PC compared to 33 non-malignant (NM) prostate tissue samples. This was validated in
an independent patient sample set comprising 497 PC and 50 NM prostate tissue samples, analyzed
on the Illumina 450K DNA methylation array (450K). Using matched RNA sequencing (RNAseq)
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data, we also found that TFF3 RNA levels were significantly upregulated in PC compared to NM
prostate tissue samples as well as significantly inversely correlated with promoter methylation levels,
consistent with epigenetic regulation of TFF3 gene activity. Moreover, low TFF3 RNA expression was
significantly associated with high ERG expression, high Gleason score, advanced pathological T-stage,
and PSA recurrence after RP. In contrast, there was no significant association between TFF3 promoter
methylation levels, ERG status, and PSA recurrence risk in these RP cohorts.
2. Results
2.1. Hypomethylation of the Trefoil Factor 3 (TFF3) Promoter Region in Prostate Cancer (PC) Samples
To investigate the diagnostic potential of TFF3 promoter hypomethylation, we used qMSP
to analyze TFF3 promoter methylation levels in 15 BPH, 18 adjacent normal (AN), 11 prostate
intraepithelial neoplasia (PIN), and 292 PC tissue samples from a large RP cohort with long
clinical follow-up (Table 1, Figure 1A). The qMSP assay was designed to cover the most frequently
hypomethylated region of the TFF3 promoter (CpG sites Nos. 6–8), as identified previously by
bisulfite sequencing [36]. TFF3 was significantly hypomethylated in RP (PC) compared to BPH and
AN samples (p < 0.001, Figure 1B), whereas no significant difference in methylation levels were
observed between BPH and AN samples (p = 0.800, Figure 1B). Pre-malignant PIN lesions were
significantly hypomethylated compared to non-malignant (BPH and AN) prostate tissue samples
(p = 0.010, Figure 1B), suggesting that loss of TFF3 promoter methylation may be an early event in
prostate carcinogenesis.
By receiver operating characteristics (ROC) curve analysis, TFF3 promoter hypomethylation
was highly cancer-specific when comparing RP to BPH samples (area under the curve (AUC) 0.908,
Figure 1C) and to AN samples (AUC 0.883, Figure 1D). Furthermore, at a sensitivity of 86.7%, the
specificity of TFF3 hypomethylation for RP vs. BPH samples was 87.3%, and at a sensitivity of
83.3% for RP vs. AN samples the specificity was 82.1%. These results are similar to the AUC
values, sensitivities, and specificities previously reported for promoter hypermethylation marker
candidates for PC diagnosis [5,6,8,37]. In comparison, serum PSA only showed an AUC of 0.738 for
distinguishing RP and BPH patients in our cohort (Figure 1E). Thus, the TFF3 promoter was frequently
hypomethylated in PC and loss of TFF3 promoter methylation was highly cancer-specific in this RP
cohort, indicating promising diagnostic potential.
To validate the cancer-specific hypomethylation of TFF3 in an independent RP patient cohort, we
analyzed 450K data from TCGA for 497 PC and 50 AN tissue samples (Table 1) [38]. Out of nine CpG
sites interrogated by probes on the 450K array and annotated to the TFF3 gene, three were located
near the qMSP assay (Illumina ID: cg21970261, cg04806409, and cg14283447, Figure 1A) and were
significantly hypomethylated in PC compared to AN samples (p ≤ 0.010, Figure 1F and Figure S1A,B),
corroborating our qMSP results (Figure 1B). None of the other six CpG sites/probes were significantly
hypomethylated in PC samples. The CpG site with the largest difference in β-values between AN and
PC samples was cg04806409, which was located downstream of the qMSP assay, and had an AUC of
0.774 (Figure 1G). We note, however, that the difference in median methylation levels between PC
and AN samples (Figure 1F and Figure S1A,B) as well as the corresponding AUC values (0.610–0.774,
Figure 1G and Figure S1C,D were smaller for the Illumina sites compared to CpG sites Nos. 6–8
(Figure 1B,D). This is in agreement with our previous bisulfite sequencing results that also showed
CpG sites Nos. 6–8 to be more frequently hypomethylated in PC tissue samples than the upstream
CpG site No. 4 [36], and together demonstrating that the methylation status of the TFF3 promoter
region is CpG site dependent.
In summary, we here report significant cancer-specific hypomethylation of the TFF3 promoter
region in two independent patient cohorts, including a total of 787 PC and 155 NM prostate
tissue samples.
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Table 1. Clinicopathologic characteristics of patient samples. For 102 of the patients analyzed by
qMSP, ERG status was available from previous IHC analyses. Abbreviations: PC, prostate cancer
samples from radical prostatectomies; AN, adjacent normal; BPH, benign prostatic hyperplasia; PIN,
prostate intraepithelial neoplasia; pT, pathological tumor stage; Pre-op, preoperative; pN, pathological
lymph node stage; IHC, immunohistochemistry; 450K, Illumina 450K DNA methylation array; qMSP,
quantitative methylation specific PCR; RNAseq, RNA sequencing; ERG, ERG, ETS transcription factor;
PSA, prostate-specific antigen.
Variable PC Samples Analyzed byqMSP (n = 292)
PC Samples Analyzed by 450K
and/or RNAseq (n = 498)
Age (years)
Median (range) 63 (46–73) 61 (41–78)
pT-stage
pT2 183 (62.7%) 188 (37.8%)
pT3 107 (36.6%) 293 (58.8%)
pT4 2 (0.7%) 10 (2.0%)
Unknown 0 (0%) 7 (1.4%)
Gleason score
<7 113 (38.7%) 86 (17.3%)
7 142 (48.6%) 240 (48.2%)
>7 36 (12.3%) 170 (34.1%)
Unknown 1 (0.3%) 2 (0.4%)
Pre-op. serum PSA (ng/mL)
Median (range) 11.8 (0.6–64.2) 7.5 (0.7–107)
0–10 114 (39.0%) 331 (66.5%)
>10 177 (60.1%) 152 (30.5%)
Unknown 1 (0.3%) 15 (3.0%)
pN-stage
pN0 252 (86.3%) 0 (0.0%)
pN1 5 (1.7%) 0 (0.0%)
Unknown 35 (12.0%) 498 (100.0%)
Surgical margin status
Negative 196 (57.9%) 316 (63.5%)
Positive 92 (31.5%) 152 (30.5%)
Unknown 4 (1.4%) 30 (6.0%)
PSA recurrence
Yes 132 (45.2%) 46 (9.2%)
No 160 (54.8%) 346 (69.5%)
Unknown 0 (0.0%) 106 (21.3%)
Follow-up (months)
Median (range) 65 (5–151) 20 (3–154)
ERG status (IHC)
Pos 59 (20.2%) 0 (0.0%)
Neg 43 (14.7%) 0 (0.0%)
Unknown 190 (65.1%) 495 (100.0%)
Non/pre-malignant samples Age/years Age/years
Median (range) Median (range)
AN (n = 18, n = 67) 62 (56–72) 61 (43–72)
BPH (n = 15) 70 (56–83) -
PIN (n = 11) 63 (54–68) -
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Figure 1. Hypomethylation of trefoil factor 3 (TFF3) in prostate cancer (PC) samples. (A) Schematic 
structure of the promoter region of TFF3 including eight CpG sites (CpG sites #1–8), 5′ UTR, 
transcription start site (TSS), and exon 1. Regions analyzed by qMSP (CpG sites Nos. 6-8) and bisulfite 
sequencing (CpG sites #1–8) are marked with arrows, indicating primer/probe positions. The 
positions of the Illumina 450K probes (cg21970261 (CpG site No. 4), cg04806409, and cg14283447) are 
indicated with black dots; (B) TFF3 methylation quantified by qMSP in BPH, AN, PIN, and RP 
samples. Median methylation and 95% confidence intervals (CI) are indicated; (C) ROC curve analysis 
of cancer specificity of TFF3 promoter methylation in BPH vs. RP samples; (D) ROC curve analysis of 
cancer specificity of TFF3 promoter methylation in AN vs. RP samples; (E) ROC curve analysis of 
cancer specificity of serum PSA levels at diagnosis in BPH vs. RP samples; (F) Promoter methylation 
of TFF3 in 450K data from TCGA (cg04806409) in AN (n = 50) vs. PC (n = 497) samples; (G) ROC curve 
analysis of cancer specificity of TFF3 promoter methylation in TCGA AN vs. PC samples for Illumina 
CpG site cg04806409. Abbreviations: 450K, Illumina 450K DNA methylation array; UTR, untranslated 
region; qMSP, quantitative methylation specific PCR; BPH, benign prostatic hyperplasia; AN, 
adjacent normal; PIN, prostate intraepithelial neoplasia; RP, radical prostatectomy; p, p-value (Mann–
Whitney U test); Grey line, median methylation. 
Figure 1. Hypomethylation of trefoil factor 3 (TFF3) in prostate cancer (PC) samples. (A) Schematic
structure of the promoter region of TFF3 including eight CpG sites (CpG sites #1–8), 5 UTR,
transcription start site (TSS), and exon 1. Regions analyzed by qMSP (CpG sites Nos. 6–8) and
bisulfite sequencing (CpG sites #1–8) are marked with arrows, indicating primer/probe positions.
The positions of the Illumina 450K probes (cg21970261 (CpG site No. 4), cg04806409, and cg14283447)
are indicated with black dots; (B) TFF3 methylation quantified by qMSP in BPH, AN, PIN, and RP
samples. Median methylation and 95% confidence intervals (CI) are indicated; (C) ROC curve analysis
of cancer specificity of TFF3 promoter methylation in BPH vs. RP samples; (D) ROC curve analysis
of cancer specificity of TFF3 promoter methylation in AN vs. RP samples; (E) ROC curve analysis of
cancer specificity of serum PSA levels at diagnosis in BPH vs. RP samples; (F) Promoter methylation of
TFF3 in 450K data from TCGA (cg04806409) in AN (n = 50) vs. PC (n = 497) sa ples; ( ) R C curve
analysis of cancer specificity of TFF3 pro oter ethylation in T vs. P sa ples for Illu ina
p site cg04806409. bbreviations: 450 , Illu ina 450 ethylation array; T , untranslated
region; qMSP, quantitative methylation specific PCR; BPH, benign prostatic hyperplasia; AN, adjacent
normal; PIN, prostate intraepithelial neoplasia; RP, radical prostatectomy; p, p-value (Mann–Whit ey
U test); Grey line, media methylation.
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2.2. Correlation between TFF3 Promoter Methylation, Clinicopathological Parameters, and ERG, ETS
Transcription Factor (ERG) Status
To assess the association between TFF3 promoter methylation levels and PC aggressiveness, we
compared DNA methylation levels with standard clinicopathological variables: age at diagnosis,
pre-operative PSA level, Gleason score, pathological tumor (pT)-stage, pathological lymph node
(pN)-stage, surgical margin, and PSA recurrence status in our large RP cohort (n = 292; Table 1).
We found a weak, but statistically significant association between TFF3 promoter hypomethylation at
CpG sites Nos. 6–8 and high pathological Gleason score (odds ratio from logistic regression = 0.264,
p < 0.001, Table 2; Mann–Whitney U test p = 0.007, Figure S2A), while there were no significant
associations with any of the other clinicopathological parameters (Figure S2B–G, Table 2).
Using a subset of samples from these RP patients (n = 102; Table 1) previously analyzed on a
TMA and scored for ERG immunoreactivity [39], we found no significant association between TFF3
promoter methylation at CpG sites Nos. 6–8 and ERG status (Figure S2H; p = 0.578, Mann–Whitney U
test). In the TCGA patient set, there was a significant difference in methylation levels between patients
with high and low ERG RNA expression at cg04806409, but the difference in median β-value was
negligible (p = 0.0065, Mann–Whitney U test, difference in median = 0.02), and we found no significant
difference in TFF3 promoter methylation at CpG sites cg21970261 and cg14283447. In summary, TFF3
promoter methylation levels are likely not affected by ERG expression levels.
Table 2. Correlation between TFF3 promoter methylation (CpG sites Nos. 6–8) and clinicopathological
variables in RP samples (n = 292). Abbreviations: OR, odds ratio; CI, confidence interval;
* p-value < 0.01.
Variable
Logistic Regression Variable Value
(Dichotomized)
Median TFF3
Methylation (95% CI)
Mann–Whitney
p-ValueOR p-Value
Age 0.999 0.992 - - -
Pre-operative PSA 0.958 0.053
0–10 ng/mL 0.13 (0.10–0.15)
0.202>10 ng/mL 0.15 (0.13–0.20)
Gleason score 0.264 <0.001 *
GS < 7 0.16 (0.13–0.22)
0.007 *GS ≥ 7 0.13 (0.11–0.15)
Pathological T-stage - - pT2 0.14 (0.12–0.19) 0.331pT3–4 0.13 (0.11–0.17)
Pathological N-stage - - pN0 0.15 (0.13–0.19) 0.367pN1 0.10 (0.00–0.44)
Margin status - - Neg 0.15 (0.12–0.19) 0.261Pos 0.14 (0.11–0.19)
PSA recurrence status - -
No 0.13 (0.10–0.15)
0.258Yes 0.16 (0.13–0.21)
ERG status (IHC) - -
Neg 0.22 (0.16–0.30)
0.578Pos 0.22 (0.15–0.28)
2.3. Survival Analysis
Next, we tested the prognostic potential of TFF3 promoter methylation for prediction of
post-operative PSA recurrence risk in our RP cohort by univariate Cox regression analysis.
High Gleason score, advanced pT-stage, positive lymph node, and positive surgical margin status were
all significantly associated with early PSA recurrence (Table 3), indicating that this is a representative
RP cohort. In contrast, no significant association was found between PSA recurrence-free survival and
age at diagnosis, ERG status, or TFF3 promoter methylation level at CpG sites Nos. 6–8, respectively
(Table 3). Similarly, in the TCGA RP cohort (n = 389), the methylation level did not predict time to PSA
recurrence at any of the three CpG sites, whereas high Gleason score and advanced pT-stage were
significantly associated with PSA recurrence (Table 4). ERG status was not associated with time to PSA
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recurrence, neither in our RP cohort (Table 3) nor in the TCGA RP cohort (Table 4), consistent with
previous reports [35].
Table 3. Cox regression analysis of PSA recurrence-free survival after radical prostatectomy in our PC
cohort (n = 292). TFF3 methylation for CpG sites Nos. 6–8. Abbreviations: Path, pathological; T, tumor;
N, lymph node; Pre-op, preoperative; HR, hazard ratio; CI, confidence interval; * p-value < 0.005.
Variable HR (95% CI) p-Value
TFF3 methylation Cont. 1.01 (0.44–2.29) 0.986
Age Cont. 0.98 (0.95–1.01) 0.136
Pre-op. PSA Cont. 1.05 (1.03–1.06) <0.001 *
Gleason score <7 vs. ≥7 2.19 (1.46–3.28) <0.001 *
Path. T-stage pT2 vs. pT3–4 3.64 (2.58–5.12) <0.001 *
Path. N-stage pN0 vs. pN1 4.00 (1.62–9.85) 0.003 *
Surgical margin status Neg vs. pos 3.28 (2.32–4.63) <0.001 *
ERG status (IHC) Neg vs. pos 1.13 (0.71–1.82) 0.606
Table 4. Cox regression analysis of PSA recurrence-free survival after radical prostatectomy in the
TCGA PC patient cohort (n = 389). TFF3 methylation for CpG site No. 4. Abbreviations: Path,
pathological; T, tumor; Pre-op, preoperative; HR, hazard ratio; CI, confidence interval; * p-value < 0.05.
Variable HR (95% CI) p-Value
TFF3 methylation, cg21970261 Cont. 1.96 (0.28–13.75) 0.497
TFF3 methylation, cg04806409 Cont. 0.04 (0.00–1.79) 0.096
TFF3 methylation, cg14283447 Cont. 0.97 (0.03–31.95) 0.985
TFF3 RNA expression Cont. 0.84 (0.74–0.97) 0.013 *
Age Cont. 1.02 (0.97–1.06) 0.479
Pre-op. PSA Cont. 1.02 (1.00–1.04) 0.065
Path. Gleason score <7 vs. ≥7 4.75 (1.15–19.61) 0.031 *
Path. T-stage pT2 vs. pT3–4 6.02 (2.16–16.81) 0.001 *
Surgical margin status Neg vs. pos 1.47 (0.82–2.65) 0.198
ERG RNA expression Low vs. high 0.95 (0.50–1.63) 0.741
2.4. TFF3 RNA Expression Patterns in Public Datasets for PC
Using RNAseq data from TCGA [38], we evaluated TFF3 transcriptional expression levels in
495 PC and 52 AN prostate tissue samples. TFF3 RNA was significantly upregulated in PC compared
to AN samples (p < 0.001, Figure 2A), consistent with promoter hypomethylation in PC (Figure 1B,F).
At the RNA level, TFF3 showed only moderate diagnostic biomarker potential by ROC curve analysis
(AUC 0.715, Figure 2B). Furthermore, matched RNAseq and 450K data were available for 494 PC
and 35 AN tissue samples [38] and demonstrated a significant inverse correlation between RNA
expression and TFF3 promoter methylation at two out of three CpG sites (cg21970261: Spearman’s
$ = −0.406, p < 0.001, Figure 2C; cg14283447: Spearman’s $ =−0.295, p < 0.001, Figure S3B; cg04806409,
p > 0.05, Figure S2A), thereby corroborating and expanding our previous findings in a small set of
prostatic cell lines [36], and together suggesting that epigenetic changes are associated with TFF3
upregulation in PC.
The significant upregulation of TFF3 RNA expression in PC was confirmed in two additional
patient sample sets, including 126 PC + 29 AN and 36 PC + 19 AN [40,41] tissue samples profiled
on microarrays (p < 0.001 and p = 0.019; Figure S4A,B), and also had similar AUCs (0.727 and 0.716
by ROC curve analysis). Overexpression of TFF3 RNA was specific for ERG negative PC in all
of the three independent patient sets (Figure 2D and Figure S4C,D), corresponding to previous
findings at the TFF3 protein level [33,42] and consistent with previous reports that the TFF3 gene
is downregulated by ERG [42]. In further agreement with this, TFF3 and ERG RNA expression
levels were significantly inversely correlated in all of the three public RNA expression datasets
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investigated (Spearman correlation test, TCGA: $ = −0.604, p < 0.001, Taylor et al.: $ = −0.697,
p < 0.001; Mortensen et al.: $ = −0.695, p < 0.001) [38,40,41].
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patient cohort (495 PC and 52 AN). Low TFF3 RNA expression was significantly associated with high 
Gleason score and with advanced pathological T-stage (p < 0.001, Mann–Whitney U test; Figure 2E,F), 
whereas no significant association with pre-operative PSA level (p = 0.829; Spearman correlation test) 
or surgical margin status (p = 0.151; Mann–Whitney U test) was found (Figure S5A,B). In contrast, 
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expression in AN vs. PC samples; (C) Correlation between TFF3 promoter methylation (cg21970261;
CpG site No. 4) and TFF3 RNA expression in AN (n = 35, grey) and PC (n = 494, black) samples
from TCGA. Correlations between TFF3 RNA expression and (D) ERG RNA expression (n = 495),
(E) Gleason score (n = 493), and (F) pathological T-stage (n = 488). Abbreviations: CPM, counts per
million; AN, adjacent normal; PC, prostate cancer; p, p-value (Mann–Whitney U test or Spearman’s
correlation test); $, Spearman’s rho; pT, pathological T-stage; Grey line, median expression.
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correlation bet een FF3 ex ression an clinico athological variables in the large
atient cohort (495 an 52 ). o FF3 ex ression as significantly associate ith high
leason score an ith a vance athological -stage (p 0.001, ann– hitney test; Fig re 2 ,F),
hereas no significant association ith re-o erative S level (p 0.829; S ear an correlation test)
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or surgical margin status (p = 0.151; Mann–Whitney U test) was found (Figure S5A,B). In contrast,
low TFF3 RNA expression was significantly associated with early PSA recurrence in univariate Cox
regression analysis (HR 0.84 (0.74–0.97), p = 0.013, Table 4), suggesting that TFF3 RNA expression has
prognostic biomarker potential for PC. Although TFF3 RNA expression did not remain significant after
correction for Gleason score and pT-stage (p = 0.177; Table S1) in this patient cohort with relatively
limited follow-up and few PSA recurrences (Table 1), Kaplan–Meier analyses showed that PC patients
with low TFF3 expression had significantly increased risk of PSA recurrence (Figure 3A, p = 0.039,
log-rank test).
ERG RNA expression levels did not have significant prognostic value for prediction of
recurrence-free survival in the TCGA cohort (p = 0.741, univariate cox regression analysis; Table 4).
However, when grouping PC patients according to ERG expression status (low or high), the prognostic
potential of TFF3 expression remained significant in univariate cox regression analysis in both the
ERG low (HR 0.79 (0.67–0.94), p = 0.008) and the ERG high subgroup (HR 0.84 (0.74–0.97), p = 0.013),
which was also confirmed by Kaplan–Meier analysis (Figure 3B,C, p = 0.049 and p = 0.043, log-rank
test). In conclusion, these results indicate that low transcriptional expression of TFF3 is a significant
adverse predictor for PSA recurrence after prostatectomy in both ERG negative and ERG positive PC.
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3. isc ssio
o t e best of o r k o le ge, t is is t e largest st y of FF3 ro oter et ylatio a
ex ressio i to ate. e fo t at t e FF3 ge e ro oter as freq e tly y o et ylate i
co pared to non-malignant prostate tissue samples, suggesting diagnostic biomarker potential for
PC. Additionally, TFF3 RNA expression levels were significantly increased in PC tissue samples and
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correlated inversely with TFF3 promoter methylation, consistent with epigenetic regulation of gene
activity. Furthermore, low TFF3 RNA levels were significantly associated with high ERG expression,
high Gleason score, advanced pT-stage, and early PSA recurrence after RP. Together, our results
demonstrate diagnostic biomarker potential of TFF3 promoter hypomethylation as well as prognostic
biomarker potential of TFF3 RNA expression for clinically localized PC.
We assessed the diagnostic biomarker potential of TFF3 at the promoter methylation as well as
RNA expression level in multiple large RP patient cohorts. Whereas RNA expression and promoter
methylation at the 450K CpG sites in the TFF3 promoter had moderate diagnostic value (AUC range:
0.610–0.774), hypomethylation of CpG sites Nos. 6–8 was highly cancer-specific (AUC 0.908; BPH vs.
RP) and superior to serum PSA in our patient cohort (AUC 0.738). The diagnostic accuracy (AUC value)
demonstrated in the present study for TFF3 promoter hypomethylation at CpG sites Nos. 6–8 is similar
to that of previously reported candidate hypermethylation markers for PC [5,6,8–10], including one of
the most well-described methylation markers GSTP1 [43,44]. Furthermore, the results of this large-scale
study expand and confirm our previous finding of TFF3 promoter hypomethylation in PC, which was
based only on a small patient sample set (10 PC vs. 12 BPH) [36].
The relatively high rate of false-negative prostate biopsies remains a major clinical challenge for
PC diagnosis and results in many repeat biopsies [45,46]. As the biopsy procedure is associated with
considerable risk of sepsis [47], unnecessary biopsies should be avoided. Thus, it would be of potential
future clinical relevance to investigate the possible existence of PC-associated TFF3 hypomethylation
field effects in morphologically non-malignant prostate needle biopsies, which in turn might be used
to predict the need for repeat biopsy. The existence of epigenetic cancer field effects in relation to PC
has previously been reported for a number of aberrantly hypermethylated genes [48–51], but further
studies are needed to investigate if this is also the case for TFF3 promoter hypomethylation. Moreover,
non/minimally-invasive biomarkers that can accurately predict the need for initial/repeat prostate
biopsy are still lacking. Accordingly, future studies should also investigate the diagnostic biomarker
potential of TFF3 hypomethylation in plasma and urine samples.
Of note, in addition to PC samples, TFF3 was also hypomethylated in a small set of PIN samples
(n = 11). At present, it is not clear how men with high grade PIN should be treated, however, current
recommendations suggest that men included in screening studies should undergo re-biopsy within
six months after a diagnosis of multifocal high-grade PIN [52]. Thus, it is possible, that biomarkers
reporting PIN as well as PC, such as TFF3 hypomethylation, may be advantageous, either alone or in
combination with PC specific biomarkers.
In the present study, TFF3 RNA levels were significantly increased in 495 PC compared to
52 benign tissue samples. Furthermore, this is the first study to demonstrate a significant association
between low TFF3 RNA levels in PC samples and high pT-stage (n = 488), high Gleason score (n = 493),
and PSA recurrence after RP (n = 389). In agreement with our results, TFF3 protein was previously
reported to be overexpressed in malignant compared to benign prostate tissue samples in three TMA
studies, including 268, 235, and 96 RP samples, respectively [30–32]. Moreover, TFF3 immunoreactivity
was significantly lower in high-stage than low-stage PC in one of these studies [30] and a similar trend
was observed in another study [32], consistent with our results. However, in contrast to our findings at
the transcriptional level, none of the previous TMA studies found significant associations between
PSA recurrence after RP and TFF3 protein IHC scores. Differences in the exact composition and size
of RP cohorts used may explain these seeming discrepancies in prognostic potential for TFF3 at the
transcriptional and protein expression level. In addition, median follow-up times were not reported
in the TMA studies [30–32], potentially compromising the interpretation of patient outcome results.
The reported differences in prognostic potential of TFF3 protein IHC scores and RNA levels for PC
might also be explained by the use of different methodologies. IHC scores are semi-quantitative and
lack dynamic range compared to RNAseq, which offers a quantitative digital measurement of RNA
levels. Moreover, post-transcriptional regulatory mechanisms as well as secretion of TFF3 protein [53]
could make a direct comparison between TFF3 RNA and protein expression levels problematic. Lastly,
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we would suggest that cellular localization of TFF3 protein should be analyzed together with expression
levels, as localization has been suggested to impact the association between TFF3 protein and cancer
aggressiveness in breast cancer [23]. Additional large PC patient cohorts should be analyzed for TFF3
RNA expression to further validate the prognostic value reported here for TFF3 at the transcriptional
level. This should include cohorts with long clinical follow-up, to assess if TFF3 RNA levels could
have independent prognostic value.
In this study, TFF3 and ERG transcriptional expression levels in PC tissue samples were
significantly inversely correlated, as also previously reported for hormone-naive PC [31,42]. Notably,
the prognostic potential of TFF3 RNA expression for post-operative PSA recurrence remained
significant in both subgroups, suggesting that it is independent of ERG status. While this is the
first report to investigate the prognostic potential of TFF3 expression in patients stratified according to
ERG status (RNA levels low or high), further studies are needed to confirm our findings.
Currently, many patients with low-stage/low-grade PC are believed to be over-diagnosed and
over-treated [54]. New prognostic biomarkers may be used to stratify these patients into high- and
low-risk subgroups in order to guide treatment selection [55]. Thus, future studies should evaluate
whether TFF3 RNA levels in prostate biopsies can be used to stratify low-intermediate risk PC patients
for e.g., active surveillance or RP at the time of diagnosis. In such future studies, it would also be
relevant to compare the prognostic value of TFF3 RNA expression to previously published RNA
expression signatures associated with aggressiveness of early-stage PC [56] and to determine if TFF3
can improve the prognostic value of such signatures.
In the present study, we identified significant associations between low TFF3 RNA levels and high
Gleason score, advanced pT-stage, and early PSA recurrence after RP. Thus, our results indicate that low
TFF3 RNA expression is an adverse prognostic factor in PC. This might appear to contradict previous
functional studies in PC cell lines (cells isolated from metastatic disease), where high TFF3 expression
has been suggested to have an oncogenic role in late stage PC [29]. However, other reports indicate
that TFF3 may function as an oncogene or as a tumor suppressor depending on the cellular context.
Thus, in breast cancer, high TFF3 protein expression has been associated with low grade disease in
early stages, but with aggressive disease in advanced stages [23]. Furthermore, in gastric cancer, high
TFF3 protein levels have been associated with reduced overall survival only in lymph-node positive
and highly undifferentiated tumors [26], suggesting that high TFF3 protein levels are associated with
aggressiveness specifically in advanced gastric cancer. Further underlining that TFF3 can function as
an oncogene or a tumor suppressor depending on the cell type, previously reported functional studies
have shown that TFF3 overexpression promoted proliferation in a breast cancer cell line, but inhibited
proliferation in a thyroid cancer cell line [24]. Furthermore, whereas high TFF3 protein levels in colon
cancer have been associated with early recurrence after surgery [25], high TFF3 expression in ovarian
cancer is associated with longer recurrence-free survival [22]. Thus, TFF3 may serve oncogenic or
tumor suppressive functions depending on cell type and disease stage in at least some malignancies.
The different functional roles of TFF3 have been proposed to be related to the polarity of TFF3 secretion
from the cells [23]. Thus, well-differentiated tumors may retain cell polarity allowing TFF3 to be
secreted from the apical epithelial cell surface into, e.g., the lumen of glandular tissues, whereas
in poorly differentiated tumors, TFF3 may be secreted into the stroma, where it can stimulate cell
proliferation and migration, as shown in functional studies in cell line models of advanced PC [29].
Further studies are needed to investigate this in PC.
In conclusion, we have demonstrated highly significant and frequent cancer-specific promoter
hypomethylation of TFF3 in malignant compared to non-malignant prostate tissue samples in two
large independent RP cohorts, including a total of 789 PC and 94 NM tissue samples. Furthermore,
we found a significant inverse correlation between DNA methylation and RNA expression levels for
TFF3, indicating epigenetic regulation of TFF3 gene activity. Moreover, low TFF3 RNA expression was
significantly associated with early PSA recurrence after RP, suggesting that TFF3 RNA expression has
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prognostic biomarker potential for PC. This is the largest study to date investigating the promoter
methylation and RNA expression of TFF3 in PC.
4. Materials and Methods
4.1. Patient Material
The RP cohort used for quantitative methylation specific PCR (qMSP) consisted of consecutive
curatively intended RPs of histologically verified clinically localized prostate cancer (PC), as previously
described [5,6,8].
In brief, formalin-fixed paraffin-embedded (FFPE) RP samples were collected in Denmark at
Department of Urology, Aarhus University Hospital from 1997 to 2005, and in Switzerland at University
Hospital Zurich from 1993 to 2001. Hematoxylin and eosin (HE) stained slides from each patient
was evaluated by a trained pathologist, and punch biopsies of 1.5 mm from the corresponding FFPE
blocks were attained from representative regions with more than 90% tumor content. Patients with
pre/post-endocrine treatment (n = 40) or lack of follow-up (n = 56) and samples with a poor DNA
quality (n = 69) were omitted from the study. The final analysis included 292 RP patients (Table 1).
In addition, samples of benign prostatic hyperplasia (BPH, n = 15), adjacent normal (AN,
n = 18), and prostate intraepithelial neoplasia (PIN, n = 11) were included (Table 1), as described
previously [5,6,8]. Briefly, AN and PIN samples were obtained by punch biopsy of FFPE RP specimens,
whereas BPH samples were obtained from FFPE tissue from transurethral resections of the prostate.
The Danish RP samples were previously used for generation of a tissue microarray (TMA) [8,39],
and were classified as ERG positive or negative based on ERG immunohistochemistry scores [39],
which are known to closely reflect ERG fusion status [57,58].
4.2. Quantitative Methylation Specific PCR (qMSP)
For the FFPE samples collected in Denmark, DNA was extracted with the gDNA Eliminator
columns from the miRNeasy FFPE Kit (Qiagen, Hilden, Germany), and for FFPE samples collected in
Switzerland, DNA was extracted with the the Blood and Cell Culture DNA Kit (Qiagen). The EZ-96
DNA Methylation-Gold KitTM (Zymo, Irvine, CA, USA) was used for bisulfite conversion of extracted
genomic DNA, as previously described [5,6,8].
The probe and primers (Table S2) used for qMSP, targeted the promoter region of TFF3.
Furthermore, a MYOD1 assay targeting a genomic region without CpG sites was used as a control
assay, as previously described [5]. Triplicate qMSP reactions (5 µL) was run on each patient sample, on
standard curves of serially diluted methylated DNA, and on bisulfite converted and un-converted
CpGenome Universal Methylated and Unmethylated DNA (Millipore, Billerica, MA, USA) as controls.
A total of 5 ng bisulfite converted DNA was used as input, and reactions included 3 pmol of each
primer and 1 pmol probe as well as Taqman universal Mastermix no UNG (Applied Biosystems, Foster
City, CA, USA). Reactions were pippeted using the Biomek NXP Laboratory Automation Workstation
and run on the 7900 HT real time thermal cycler (Applied Biosystems): 2 min at 50 ◦C, 10 min at 95 ◦C,
and 50 cycles of 15 s at 95 ◦C and 1 min at 56 ◦C. TFF3 and MYOD1 quantities were estimated from the
standard curve using SDS 2.4 software (Applied Biosystems), and TFF3 methylation was normalized
to MYOD1 to control for DNA input. Samples were excluded from the analysis if two out of three Ct
values for MYOD1 exceeded 36. Furthermore, outliers that were more than 2 Ct values lower/higher
than the other Ct values were removed.
Bisulfite sequencing results from seven prostate cell lines (LNCaP, VCaP, DuCaP, PC3, BPH1,
DU145, and PNT1A) from our previous study [36], were used to test the specificity of our qMSP
assay. PCR primers used for bisulfite sequencing are listed in Table S2. We found that the qMSP
assay reported fully methylated alleles accurately but slightly underestimated methylation levels of
heterogeneously methylated DNA (Pearson: 0.87, p = 0.005, Figure S6A,B, compare, e.g., methylation
levels of LNCaP, VCaP, and DUCaP).
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4.3. Microarray and RNAseq Data
Illumina 450K DNA methylation array (450K, 497 RP and 50 matched AN samples), RNA
sequencing (RNAseq, 495 RP and 52 matched AN samples), and clinical data were downloaded
from The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/) (Table 1) [38]. The 450K
data were peak corrected, as previously described [59], and the methylation level for each CpG site
was given as a β-value (ranging from 0 to 1). RNAseq data from TCGA were mapped to the human
genome (hg19) using Tophat [60] and the Bowtie aligner [61], and HTSeq [62] was used to summarize
reads per gene. Gene expression quantified by RNAseq is given as counts per million (CPM).
Furthermore, normalized microarray RNA expression data and clinical data were downloaded
for 126 PC samples and 29 matched AN samples from GEO (GSE21034; Affymetrix Human Exon 1.0
ST array) [40] and for 36 PC and 14 normal prostate samples from GEO (GSE46602; Affymetrix U133
2.0 Plus microarray) [41].
4.4. Statistical Analysis
All statistical analyses were performed in STATA v. 13.1 (STATA, College Station, TX, USA).
Mann–Whitney U tests, ROC analyses, two-sided log-rank tests, univariate Cox regression analyses
and/or Kaplan–Meier analysis, using PSA recurrence (cutoff ≥ 0.2 ng/mL) as endpoint, were used to
investigate the diagnostic and prognostic potential of TFF3 promoter methylation and RNA expression.
For patients that had not experienced PSA recurrence, the last normal PSA measurement was used
as endpoint. Pearson correlations were used to compare the performance of the designed qMSP
assay to previous bisulfite sequencing results [36], Spearman correlations were used to examine the
correlation between TFF3 promoter methylation and RNA expression, and Mann–Whitney U tests
were used to investigate the association between TFF3 promoter methylation and RNA expression to
clinicopathological parameters. For all PC samples in the TCGA RNAseq data, TFF3 RNA expression
was dichotomized separating the patients into two equally sized subgroups (low and high TFF3
expression), as ROC curve analysis did not result in an obvious cutoff. Statistical significance in
Kaplan–Meier analysis was calculated using two-sided log-rank tests.
4.5. Ethical Approval
The study was approved in Switzerland by the Ethical Committee of the Canton of Zurich
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2000/0299, and the Data Protection agency approval number 2013-41-2041.
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Abbreviations
450K Illumina 450K DNA methylation array
AN Adjacent normal
AUC Area under the curve
BPH Benign prostatic hyperplasia
CI Confidence interval
CPM Count per million
FFPE Formalin-fixed paraffin embedded
HE Hematoxylin and eosin
HR Hazard ratio
NM Non-malignant
OR Odds ratio
Path Pathological
PC Prostate cancer
PIN Prostatic intraepithelial neoplasia
PSA Prostate specific antigen
qMSP Quantitative methylation specific PCR
RNAseq RNA sequencing
ROC Receiver operating characteristics
RP Radical prostatectomy
TCGA The Cancer Genome Atlas
TFF3 Trefoil factor 3
TMA Tissue microarray
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